(PharmaNewsWire.Com, May 29, 2017 ) As per the report published by Market Data Forecast Europe Psoriasis Drugs Market which is expected to be USD 2.4 billion in 2016 is poised to reach USD 3.5 billion by 2021, at a CAGR of 7.36% from 2016 to 2021. It can attribute to the factors such as approval of new drugs (interleukin-17 inhibitor, Taltz - ixekizumab by Eli Lily), increasing public awareness, and boost in psoriasis Research and Development investment. The key constraints of the market are side effects from the systemic and biologics medication, high cost involved in drug development, patent expiry of brand name drugs, and health insurance issue.
Psoriasis is non communicable inflammatory skin condition that alters the life cycle of skin cells by speeding up the growth of cells on the surface of the skin. Rapid development of cells produces thick, silver scales, and makes the skin red, flaky, dry, and itchy. Presently, no permanent cure is available for the disease; however preventative measures can be adopted to slow down the growth of skin cells on the surface of the skin. Psoriasis can be treated either with biopharmaceuticals or pharmaceuticals therapies through systemic or topical process. These medications administered either by consumed orally, or applying on the skin, or through injections specifically block parts of immune system process by specifically targeting Tumour Necrosis Factor, Interleukin, Phosphodiesterase Type 4, among others. In Europe, as per European Federation of Pharmaceutical Industries and Associations approximately 3.7 million people are affected by psoriasis. Europe Psoriasis Drugs Market is segmented based on Drug Type, Route of Administration, and Target as mentioned below for attaining a more granular perspective of the market. In the report each sub segment is provided with Market Size Estimations and Y-o-Y Forecasts.
Based on Drug Type: Introduction Pharmaceuticals Biopharmaceuticals Y-o-Y Growth Analysis, By Drug Type Market Attractiveness Analysis, By Drug Type Market Share Analysis, By Drug Type Based on Route of Administration: Introduction Topical Systemic Oral Intravenous Other Y-o-Y Growth Analysis, By Route of Administration Market Attractiveness Analysis, By Route of Administration Market Share Analysis, By Route of Administration Based on Target: Introduction Tumour Necrosis Factor (TNF) Phosphodiesterase Type 4 (PDE4) Interleukin Others Y-o-Y Growth Analysis, By Target Market Attractiveness Analysis, By Target Market Share Analysis, By Target
Geographically the Europe market is segmented into Germany, Spain, U.K., France, and Italy.
The key players in Europe Psoriasis Drugs Market are Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Stiefel Laboratories Inc (USA), Celgene Corporation (USA), Takeda Pharmaceutical Company Limited (Japan), Johnson & Johnson (USA), Janssen Biotech Inc (USA), Amgen (USA), and AbbVie (USA).
Events affecting sellers, producers and developers: Research and development, including monoclonal antibodies, PDE4, TNF, IL-12, IL-17, IL-23, JAK and T-cell inhibition, and histamine receptor antagonism Prevalence of that skin disease, as well as issues for healthcare providers and patients estimate treatment needs Competition from biosimilars, generic drugs, and new biologics Companies specializing in autoimmune and dermatology disorders explore capabilities and emerging trends to treat psoriasis Advances in drug delivery to benefit patients, payers, and companies, including ointment, lotion, and foam
The Psoriasis Drugs Market study offers the following deliverables:
Regional and country-level analysis that provides an innate perspective of European region and the aforementioned countries Meticulously identifying the key areas of market growth by providing market size forecasts and y-o-y estimations at a Segment-level analysis Explanations of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics Study of macro and micro environmental factors that affect the European market presented in the form of PESTLE and Porters Five Forces Analyses Company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and analyst overview of the key market players operating in the region Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies Expertly devised Market Outlook - Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Pharmaceuticals Segment:
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialties with competitive pricing options.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
